The latest ASX stocks upgraded by brokers to “buy” today

The ASX 200 is poised to end the week on a backfoot. But the pullback is giving brokers the opportunity to upgrade some ASX stocks to “buy”.
The post The latest ASX stocks upgraded by brokers to “buy” today appeared first on Motley Fool Australia. –

The market is poised to end the week on a backfoot. But the pullback is giving brokers the opportunity to upgrade some ASX stocks to “buy”.

The S&P/ASX 200 Index (Index:^AXJO) slumped 0.7% in after lunch trade and will finish the week with a 1% loss if it closes at current levels.

While experts are divided on whether the burst in volatility marks the start of a highly anticipated market correction, top brokers are seeing value in two stocks.

Floating to the top

The Santos Ltd (ASX: STO) share price is one with UBS upgrading its recommendation on the stock to “buy” from “neutral”.

The news isn’t helping the stock today though as the slump in the overnight oil price dragged on the sector.

But Santos can still be a profitable play even as the Brent crude price dropped under US$40 a barrel. UBS believes management can achieve its target of being free cash flow (FCF) breakeven at under US$25 a barrel this calendar year.

This will help Santos lower gearing to 27% from 34% by FY22 – just in time for its next major growth phase.

Underappreciated assets

But this isn’t the only reason to buy the stock. The broker believes the market is underappreciating a number of its assets.

The 1.7 million tonnes a year (mtpa) Moomba Carbon Capture and Storage (CCS) project is one. Moomba could benefit Santos in two ways.

“We anticipate [the] federal govenment will likely legislate a process for CCS to be eligible for Australian Carbon Credit Units (ACCUs) offsetting >50% of the lifecycle cost,” said UBS.

“Our analysis expects that reinjecting 1.7mtpa of CO2 into depleted Cooper basin reservoirs could lift oil production by 2.7mmbbl pa.”

The broker’s price target on Santos is $6.50 a share.

Spoonful of sugar

Meanwhile, Credit Suisse upped its rating today on the Sigma Healthcare Ltd (ASX: SIG) share price to “outperform” from “neutral”.

The broker turned bullish on the drug supplier and pharmacy retail chain as it believes the stock is cheap and can deliver double-digit earnings growth.

“We forecast SIG achieving EBITDA CAGR of 21% between FY20-FY23F driven by cost outs, full ramp-up of Chemist Warehouse FMCG contract and continued above market growth in retail,” said Credit Suisse.

“The stock trades on 17x 12-mth forward CS EPS, below its two- and 5-year averages.”

Cash conversion set to improve

Sigma reported its first half results this week, which was inline with the broker’s expectations, although its cash conversion of 49% may have disappointed investors.

But Credit Suisse believes this will improve once the volatility from the COVID-19 impact subsides.

The broker’s 12-month price target on the stock is $0.70 a share.

These stocks could rocket in a Post-COVID world (FREE STOCK REPORT)

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

Find out the names of our 3 Post COVID Stocks – For FREE!

*Returns as of 6/8/2020

More reading

Motley Fool contributor Brendon Lau has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post The latest ASX stocks upgraded by brokers to “buy” today appeared first on Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!